Use of silver nanoparticles increased inhibition of cell-associated HIV-1 infection by neutralizing antibodies developed against HIV-1 envelope proteins

Journal of Nanobiotechnology

Volumn 9, Issue , 2011, Pages

  Lara, Humberto H ^a   Ixtepan Turrent, Liliana ^b   Garza Treviño, Elsa N ^b   Singh, Dinesh K ^a  

^a WINSTON SALEM STATE UNIVERSITY   (United States)

^b UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

Author keywords

Gp120; Gp41; HIV; Neutralizing Antibodies; Silver Nanoparticles

Indexed keywords

GP120; GP41; HIV; NEUTRALIZING ANTIBODIES; SILVER NANOPARTICLES;

CELLS; CYTOLOGY; MONOCLONAL ANTIBODIES; NANOPARTICLES; PROTEINS; SILVER; VACCINES; VIRUSES;

DISEASES;

HIV 1 GP120 ANTISERUM PB1 [24 26]; HIV 1 GP120 ANTISERUM PB1 SUB 2; HIV 1 GP120 MONOCLONAL ANTIBODY F425 B4E8; MONOCLONAL ANTIBODY TO HIV 1 GP41 126 7; NEUTRALIZING ANTIBODY; SILVER NANOPARTICLE; UNCLASSIFIED DRUG; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; METAL NANOPARTICLE; SILVER; VIRUS ENVELOPE PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CELL FREE SYSTEM; DOSE RESPONSE; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; VIRUS INHIBITION; VIRUS TRANSMISSION; CHEMISTRY; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; TUMOR CELL LINE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

AIDS VACCINES; ANTIBODIES, NEUTRALIZING; CELL LINE, TUMOR; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; METAL NANOPARTICLES; SILVER; VIRAL ENVELOPE PROTEINS;

EID: 80052863000     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/1477-3155-9-38     Document Type: Article

References (28)

1. Fauci AS. The AIDS epidemic--considerations for the 21st century. N Engl J Med 1999, 341:1046-1050. 10.1056/NEJM199909303411406, 10502595.
2. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860. 10.1056/NEJM199803263381301, 9516219.
3. Vittinghoff E, Scheer S, O'Malley P, Colfax G, Holmberg SD, Buchbinder SP. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis 1999, 179:717-720. 10.1086/314623, 9952385.
4. Bansi L, Smith C, Phillips A, Kirk S, Geretti AM, Johnson M, Mackie N, Post F, Gazzard B, Dunn D, Sabin C. The impact of HIV drug resistance testing on changes to treatment. AIDS 2011, 25:603-610. 10.1097/QAD.0b013e32834403a0, 21297420.
5. Perno CF. The discovery and development of HIV therapy: the new challenges. Ann Ist Super Sanita 2011, 47:41-43.
6. Whaley KJ, Hanes J, Shattock R, Cone RA, Friend DR. Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines. Antiviral Res 2010, 88(Suppl 1):S55-S66.
7. Blais ME, Rowland-Jones S. Lessons from the failure of the adenovector HIV vaccine. F1000 Biol Rep 2009, 1:50. 2924706, 20948634.
8. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, Koff WC, Watkins DI, Burton DR. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 2009, 5:1000433.
9. Klasse P, Sanders R, Cerutti A, Moore J. How can HIV-1 Env immunogenicity be improved to facilitate antibody-based vaccine development?. AIDS Res Hum Retroviruses 2011,
10. Lansdown AB. A pharmacological and toxicological profile of silver as an antimicrobial agent in medical devices. Adv Pharmacol Sci 2010, 2010:910686. 3003978, 21188244.
11. Lara HH, Ayala Nuñez NV, Ixtepan Turrent L, Rodriguez-Padilla C. Bactericidal effect of AgNPs against multidrug-resistant bacteria. Word Journal Microbiology Biotechnology 2010, 26:615-621.
12. Ayala Nuñez NV, Lara HH, Ixtepan Turrent L, Rodriguez-Padilla C. AgNPs Toxicity and Bactericidal Effect Against Methicillin-Resistant Staphylococcus aureus: Nanoscale Does Matter. Nanobiotechnology 2009, 5:1-4.
13. Zuppa AA, D'Andrea V, Catenazzi P, Scorrano A, Romagnoli C. Ophthalmia neonatorum: what kind of prophylaxis?. J Matern Fetal Neonatal Med 2011, 24:769-773. 10.3109/14767058.2010.531326, 21534852.
14. Muangman P, Pundee C, Opasanon S, Muangman S. A prospective, randomized trial of silver containing hydrofiber dressing versus 1% silver sulfadiazine for the treatment of partial thickness burns. Int Wound J 2010, 7:271-276. 10.1111/j.1742-481X.2010.00690.x, 20528992.
15. Vyas TK, Shah L, Amiji MM. Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites. Expert Opin Drug Deliv 2006, 3:613-628. 10.1517/17425247.3.5.613, 16948557.
16. Das NJ, Amiji MM, Bahia MF, Sarmento B. Nanotechnology-based systems for the treatment and prevention of HIV/AIDS. Adv Drug Deliv Rev 2010, 62:458-477. 10.1016/j.addr.2009.11.017, 19914314.
17. Sharma P, Garg S. Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs. Adv Drug Deliv Rev 2010, 62:491-502. 10.1016/j.addr.2009.11.019, 19931328.
18. Mamo T, Moseman EA, Kolishetti N, Salvador-Morales C, Shi J, Kuritzkes DR, Langer R, von AU, Farokhzad OC. Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomedicine (Lond) 2010, 5:269-285.
19. Villalonga-Barber C, Micha-Screttas M, Steele BR, Georgopoulos A, Demetzos C. Dendrimers as biopharmaceuticals: synthesis and properties. Curr Top Med Chem 2008, 8:1294-1309. 10.2174/156802608785849012, 18855710.
20. Elechiguerra JL, Burt JL, Morones JR, Camacho-Bragado A, Gao X, Lara HH, Yacaman MJ. Interaction of AgNPs with HIV-1. J Nanobiotechnology 2005, 3:6. 10.1186/1477-3155-3-6, 1190212, 15987516.
21. Lara HH, Ayala-Nunez NV, Ixtepan-Turrent L, Rodriguez-Padilla C. Mode of antiviral action of AgNPs against HIV-1. J Nanobiotechnology 2010, 8:1. 10.1186/1477-3155-8-1, 2818642, 20145735.
22. Lara HH, Ixtepan-Turrent L, Garza-Trevino EN, Rodriguez-Padilla C. PVP-coated AgNPs block the transmission of cell-free and cell-associated HIV-1 in human cervical culture. J Nanobiotechnology 2010, 8:15. 10.1186/1477-3155-8-15, 2911397, 20626911.
23. Yuan W, Li X, Kasterka M, Gorny MK, Zolla-Pazner S, Sodroski J. Oligomer-specific conformations of the human immunodeficiency virus (HIV-1) gp41 envelope glycoprotein ectodomain recognized by human monoclonal antibodies. AIDS Res Hum Retroviruses 2009, 25:319-328. 10.1089/aid.2008.0213, 2853836, 19292593.
24. Matsushita S, Robert-Guroff M, Rusche J, Koito A, Hattori T, Hoshino H, Javaherian K, Takatsuki K, Putney S. Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J Virol 1988, 62:2107-2114. 253305, 2452899.
25. Putney SD, Matthews TJ, Robey WG, Lynn DL, Robert-Guroff M, Mueller WT, Langlois AJ, Ghrayeb J, Petteway SR, Weinhold KJ. HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope. Science 1986, 234:1392-1395. 10.1126/science.2431482, 2431482.
26. Rusche JR, Lynn DL, Robert-Guroff M, Langlois AJ, Lyerly HK, Carson H, Krohn K, Ranki A, Gallo RC, Bolognesi DP. Humoral immune response to the entire human immunodeficiency virus envelope glycoprotein made in insect cells. Proc Natl Acad Sci USA 1987, 84:6924-6928. 10.1073/pnas.84.19.6924, 299197, 3477816.
27. Bell CH, Pantophlet R, Schiefner A, Cavacini LA, Stanfield RL, Burton DR, Wilson IA. Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization. J Mol Biol 2008, 375:969-978. 10.1016/j.jmb.2007.11.013, 2289799, 18068724.
28. Diane V, Edouard T, Yassine AT, Francois R, Pierre-Alain R, Nicolas M, Vincent F, Karine B, Nicolas N, Philipe VDP, Jean-Pierre V. CD4+T cells spontaneously producing HIV-1 in breast milk from women with or without antiretroviral drugs. Retrovirology 2011, 8:34. 10.1186/1742-4690-8-34, 3120758, 21569457.